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BACKGROUND: Although a high level of thymidylate synthase (TS) expression in malignant tumours has been suggested to be related to
a reduced sensitivity to the antifolate drug pemetrexed, no direct evidence for such an association has been demonstrated in non-
small cell lung cancer (NSCLC). We have now investigated the effect of TS overexpression on pemetrexed sensitivity in NSCLC cells.
METHODS: We established NSCLC cell lines that stably overexpress TS and examined the effects of such overexpression on the
cytotoxicity of pemetrexed both in vitro and in xenograft models. We further examined the relation between TS expression in
tumour specimens from NSCLC patients and the tumour response to pemetrexed by immunohistochemical analysis.
RESULTS: The sensitivity of NSCLC cells overexpressing TS to the antiproliferative effect of pemetrexed was markedly reduced
compared with that of control cells. The inhibition of DNA synthesis and induction of apoptosis by pemetrexed were also greatly
attenuated by forced expression of TS. Furthermore, tumours formed by TS-overexpressing NSCLC cells in nude mice were
resistant to the growth-inhibitory effect of pemetrexed observed with control tumours. Finally, the level of TS expression in tumours
of non-responding patients was significantly higher than that in those of responders, suggestive of an inverse correlation between TS
expression and tumour response to pemetrexed.
CONCLUSION: A high level of TS expression confers a reduced sensitivity to pemetrexed. TS expression is thus a potential predictive
marker for response to pemetrexed-based chemotherapy in NSCLC patients.
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Lung cancer is the most common cause of cancer-related death
worldwide, with non-small cell lung cancer (NSCLC) accounting
for B75% of all lung cancer cases (Hoffman et al, 2000). Platinum-
based chemotherapy is the standard first-line treatment for
individuals with advanced NSCLC, but the efficacy of such agents
with regard to improving clinical outcome is limited (Schiller et al,
2002). Both experimental and clinical studies have revealed that
many molecules contribute to the biological activities of malignant
tumours including NSCLC. New strategies based on a better
understanding of tumour biology may thus help to maximise the
efficacy of current treatments.
A relatively new antifolate drug, pemetrexed, inhibits the growth
of a variety of tumour types by targeting multiple folate-dependent
enzymes including thymidylate synthase (TS), dihydrofolate
reductase, and glycinamide ribonucleotide formyltransferase (Shih
et al, 1997). The antitumour efficacy of pemetrexed has been found
to be more limited in lung cancer patients with squamous cell
carcinoma than in those with other histotypes of NSCLC (Scagliotti
et al, 2008). Furthermore, the abundance of TS mRNA or protein
seems to be higher in squamous cell carcinoma than in other
histotypes of NSCLC (Ceppi et al, 2006; Monica et al, 2009;
Takezawa et al, 2010), and high levels of TS expression in various
tumour types have been suggested to correlate with a poor
response to TS-targeted agents (Johnston et al, 1994, 1997;
Pestalozzi et al, 1997; Ferguson et al, 1999). The poorer response
of NSCLC patients with squamous cell carcinoma to pemetrexed is
thus thought to result from the higher level of TS expression in
such tumours. However, such a relation between a high TS
expression level and a reduced sensitivity to pemetrexed in NSCLC
has not been well established. Moreover, the precise mechanism
that might underlie a reduced sensitivity to pemetrexed in tumours
with a high level of TS expression remains unknown.
We have now constructed an expression vector for TS and have
used this vector to establish several NSCLC cell lines that stably
overexpress TS. With the use of these cells, we examined the
relation between the anticancer effects of pemetrexed both in vitro
and in vivo and the expression level of TS. We further investigated
the relation between pemetrexed sensitivity and TS expression
level in primary lung cancer patients.
MATERIALS AND METHODS
Cell culture and reagents
The human lung cancer cell lines A549, H1299, and PC9 were
obtained from American Type Culture Collection (Manassas, VA, USA).
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sAll cells were cultured in RPMI 1640 medium (Sigma, St Louis,
MO, USA) supplemented with 10% fetal bovine serum and 1%
penicillin-streptomycin (Sigma), and they were maintained under
a humidified atmosphere of 5% CO2 at 371C. Pemetrexed, cisplatin,
and docetaxel were obtained from Wako (Osaka, Japan).
Generation of TS-overexpressing NSCLC cell lines
A full-length cDNA fragment encoding TS was obtained from PC9
cells by reverse transcription and the polymerase chain reaction
with the primers TS-F (50-AAGCTTCGCGCCATGCCTGTGG
CCGGCTCGGAG-30) and TS-R (50-GCGGCCGCCTAAACAGCC
ATTTCCATTTTAATAG-30). The amplification product was
verified by sequencing after its cloning into the pCR-Blunt
II-TOPO vector (Invitrogen, Carlsbad, CA, USA). The TS cDNA
was excised from pCR-Blunt II-TOPO and transferred to the pMZs
retroviral vector (Cell Biolabs, San Diego, CA, USA). The resulting
pMZs construct and the pVSV-G vector (Clontech, Palo Alto, CA,
USA) for construction of the viral envelope were introduced into
GP2-293 cells (B80% confluence in a 10-cm dish) with the use of
the FuGENE6 transfection reagent. After 48h, the viral particles
released into the culture medium were concentrated by centrifuga-
tion at 15000 g for 3h at 41C. The resulting pellet was then
suspended in fresh RPMI 1640 medium and used to infect A549,
H1299, or PC9 cells as previously described (Okamoto et al, 2010).
Immunoblot analysis
Cells were washed twice with ice-cold phosphate-buffered saline
(PBS) and then lysed in a solution containing 20mM Tris-HCl (pH
7.5), 150mM NaCl, 1mM EDTA, 1% Triton X-100, 2.5mM sodium
pyrophosphate, 1mM phenylmethylsulfonyl fluoride, and leupeptin
(1mgml
 1). The protein concentration of cell lysates was
determined with the Bradford reagent (Bio-Rad, Hercules, CA,
USA), and equal amounts of lysate protein were subjected to
SDS-polyacrylamide gel electrophoresis on a 7.5 or 12% gel. The
separated proteins were transferred to a nitrocellulose membrane,
which was then exposed to 5% non-fat dried milk in PBS for 1h at
room temperature before incubation overnight at 41C with
primary antibodies. Rabbit polyclonal antibodies to human TS
were obtained from Santa Cruz Biotechnology (Santa Cruz, CA,
USA), and those to b-actin were from Sigma. The membrane was
then washed with PBS containing 0.05% Tween 20 before
incubation for 1h at room temperature with horseradish
peroxidase-conjugated goat antibodies to rabbit immunoglobulin G
(Sigma). Immune complexes were finally detected with chemilu-
minescence reagents (GE Healthcare, Little Chalfont, UK).
Assay of TS activity
Thymidylate synthase activity was quantified with the use of a
tritiated 5-fluoro-dUMP binding assay. Cells were harvested,
diluted in 0.2 M Tris-HCl (pH 7.4) containing 20mM 2-mercapto-
ethanol, 15mM CMP, and 100mM NaF, and disrupted by ultrasonic
treatment. The cell lysate was centrifuged at 1600 g for 15min at
41C, and the resulting supernatant was centrifuged at 105000 g
for 1h at 41C. A portion (50ml) of the final supernatant was mixed
consecutively with 50ml of Buffer A (600mM NH4HCO3 buffer (pH
8.0), 100mM 2-mercaptoethanol, 100mM NaF, 15mM CMP) and
with 50ml of (6-
3H)5-fluoro-dUMP (7.8pmol) plus 25ml of cofactor
solution (50mM potassium phosphate buffer (pH 7.4), 20mM
2-mercaptoethanol, 100mM NaF, 15mM CMP, 2% bovine serum
albumin, 2mM tetrahydrofolic acid, 16mM sodium ascorbate, 9mM
formaldehyde). The resulting mixture was incubated at 301C for
20min, after which the reaction was terminated by the addition of
100ml of 2% bovine serum albumin and 275ml of 1M HClO4 and
by centrifugation at 1600 g for 15min at 41C. The resulting
precipitate was suspended in 2ml of 0.5M HClO4, and the mixture
was subjected to ultrasonic treatment followed by centrifugation at
1600 g for 15min at 41C. The final precipitate was solubilised with
0.5ml of 98% formic acid, mixed with 10ml of ACS II scintillation
fluid, and assayed for radioactivity. Data are expressed as picomoles
of substrate consumed per milligram of soluble protein.
Cell growth inhibition assay in vitro (MTT assay)
Cells were plated in 96-well flat-bottomed plates and cultured for
24h before exposure to various concentrations of drugs for 72h.
TetraColor One (5mM tetrazolium monosodium salt and 0.2mM
1-methoxy-5-methyl phenazinium methylsulfate; Seikagaku,
Tokyo, Japan) was then added to each well, and the cells were
incubated for 3h at 371C before measurement of absorbance
at 490nm with a Multiskan Spectrum instrument (Thermo
Labsystems, Boston, MA, USA).
RNA interference
Cells were plated at 50–60% confluence in six-well plates or
25-cm
2 flasks and then incubated for 24h before transient
transfection for the indicated times with small interfering RNAs
(siRNAs) mixed with the Lipofectamine reagent (Invitrogen). An
siRNA specific for human TS mRNA (50-CAAUCCGCAUCCAA
CUAUU-30) and a nonspecific siRNA (50-GUUGAGAGAUAUUA
GAGUU-30) was obtained from Nippon EGT (Toyama, Japan).
Assay of DNA synthesis
DNA synthesis was measured with the use of a Cell Proliferation
ELISA BrdU Kit (Roche, Basel, Switzerland). In brief, cells were
seeded in 96-well plates at a density of 10000–20000 per well and
exposed to various concentrations of drugs for 48h. They were
then incubated in the additional presence of bromodeoxyuridine
(BrdU) for 3h before exposure to detection reagents for 15min at
251C and measurement of luminescence.
Annexin V binding assay
Binding of annexin V to cells was measured with the use of an
Annexin-V-FLUOS Staining Kit (Roche). Cells were harvested by
exposure to trypsin–EDTA, washed with PBS, and centrifuged at
200 g for 5min. The cell pellets were resuspended in 100mlo f
Annexin-V-FLUOS labelling solution, incubated for 10–15min at
15 to 251C, and then analysed for fluorescence with a flow cytometer
(FACS Calibur) (Becton Dickinson, San Jose, CA, USA) and Cell
Quest software (Becton Dickinson).
Animals
Male athymic nude mice were maintained on a 12-h light, 12-h
dark cycle and provided with food and water ad libitum in a
barrier facility. All animal experiments were carried out with
approval of the institutional animal care and use committee and
complied with the specifications of the Association for Assessment
and Accreditation of Laboratory Animal Care of Japan.
Tumour growth inhibition assay in vivo
Cubic fragments of tumour tissue (B2b y2b y2 m m )w e r e
implanted subcutaneously into the axilla of 5- to 6-week-old male
athymic nude mice. Treatment was initiated when tumours in each
group of eight mice achieved an average volume of 150–200mm
3.
Pemetrexed (100mg per kilogram of body weight) or vehicle
(physiological saline) was administered intraperitoneally once a
week. Tumour volume was determined from caliper measurements
of tumour length (L)a n dw i d t h( W) according to the formula LW
2/2.
Both tumour size and body weight were measured twice per week.
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sPatients and clinical specimens
For retrospective analysis, we recruited consecutive patients with
advanced NSCLC who received chemotherapy at Kinki University
Hospital between April 2008 and June 2010. Patients met all of the
following criteria: a histological diagnosis of NSCLC with at least
one measurable lesion; a clinical stage of 3B or 4; an Eastern
Cooperative Oncology Group (ECOG) performance status of 0 or 1;
adequate haematologic, hepatic, and renal function; treatment
either with carboplatin at an area under the curve (AUC) of 5 on
day 1 and pemetrexed at 500mgm
 2 on day 1 of an 21-day cycle or
with cisplatin at 75mgm
 2 on day 1 and pemetrexed at
500mgm
 2 on day 1 of an 21-day cycle as first-line chemotherapy;
and availability of sufficient tumour tissue in paraffin blocks for
assessment by immunohistochemistry. Tumour tissue specimens
were obtained by transbronchial lung biopsy. Tumour response
was examined by computed tomography and evaluated according
to the Response Evaluation Criteria in Solid tumours (RECIST) as
complete response (CR), partial response (PR), stable disease (SD),
or progressive disease (PD). This study conforms to the provisions
of the Declaration of Helsinki and was approved by the local
institutional review board.
Immunohistochemistry and scoring of TS expression
Paraffin-embedded sections (thickness, 4mm) of tumour tissue
were depleted of paraffin with xylene and then rehydrated, and
endogenous peroxidase activity was quenched by incubation with
0.3% hydrogen peroxide in methanol. Antigen retrieval was carried
out by microwave irradiation for 10min in citrate buffer (pH 6.0).
The sections were then washed with PBS before incubation
overnight at room temperature with rabbit polyclonal antibodies
to TS (Taiho Pharmaceutical Co., Saitama, Japan) at a dilution of
1:100. Immune complexes were detected by incubation at room
temperature for 30min first with biotinylated goat antibodies to
rabbit immunoglobulin G (Dako, Santa Barbara, CA, USA) and
then with streptavidin-conjugated horseradish peroxidase (Dako).
Peroxidase activity was visualised with diaminobenzidine
tetrahydrochloride solution (Dako), and the sections were counter-
stained with hematoxylin before examination with a microscope
(Dako). The human colon cancer cell line DLD-1/FrUrd, human
breast cancer cell line MDA-MB-435S, and human pancreatic
cancer cell line MIAPaCa-2 (all obtained from American Type
Culture Collection) were used as positive controls for TS staining.
All immunostained sections were reviewed by two observers
without knowledge of the patients’ characteristics. Sections with
discrepant results were jointly reevaluated until a consensus was
reached. Cytoplasmic staining for TS was scored in a semiquanti-
tative manner, reflecting both the intensity of staining and the
percentage of cells with staining at each intensity. Staining
intensity was classified as 0 (no staining), þ1 (weak staining),
þ2 (distinct staining), or þ3 (strong staining). A value
designated the HSCORE was obtained as S(I PC), where I and
TS
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Figure 1 Abundance and enzymatic activity of TS in TS-overexpressing
NSCLC cell lines. Parental (P) A549, H1299, or PC9 cells or corresponding
sublines either stably overexpressing TS (TS1 and TS2) or harbouring the
empty vector (Mock) were cultured overnight in complete medium, after
which cell lysates were prepared and either subjected to immunoblot
analysis with antibodies to TS and to b-actin (loading control) (A)o r
assayed for TS activity. (B) Data are means±s.d. of triplicates from
experiments that were repeated on two additional occasions with similar
results. *Po0.05 vs the corresponding value for Mock cells (Student’s
two-tailed t-test).
Table 1 Median inhibitory concentrations (mM) for the antiproliferative
effects of chemotherapeutic agents in TS-overexpressing NSCLC cells
in vitro
Cell line Pemetrexed Cisplatin Docetaxel
A549/Mock 0.07 2.62 0.12
A549/TS1 0.38 2.37 0.12
A549/TS2 0.44 2.21 0.13
H1299/Mock 0.08 2.93 0.32
H1299/TS1 0.22 2.98 0.30
H1299/TS2 0.22 2.90 0.30
PC9/Mock 0.03 0.72 0.18
PC9/TS1 0.11 0.72 0.18
PC9/TS2 0.10 0.65 0.17
Abbreviations: NSCLC¼non-small cell lung cancer; TS¼thymidylate synthase.
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Figure 2 Effect of TS depletion on pemetrexed sensitivity in
TS-overexpressing NSCLC cells. (A) Cells of the indicated lines were
transfected or not ( ) with nonspecific (Con) or TS siRNAs for 48h, after
which cell lysates were subjected to immunoblot analysis with antibodies to
TS and to b-actin. (B) Cells transfected as in A were cultured for 72h in
complete medium containing various concentrations of pemetrexed, after
which cell viability was assessed as described in Materials and methods
section, and the median inhibitory concentration (IC50) of pemetrexed was
determined. Data are means of triplicates from experiments that were
repeated on two additional occasions with similar results. *Po0.05
(Student’s two-tailed t-test).
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sPC represent staining intensity and the percentage of cells that
stain at each intensity, respectively. The selection of a clinically
important cutoff score for TS expression was based on receiver
operating characteristic (ROC) curve analysis.
Statistical analysis
Quantitative data are presented as means±s.d. or ±s.e.m. as
indicated, and were analysed by Student’s two-tailed t-test.
Progression-free survival was assessed from the first day of
chemotherapy administration to the date of objective disease
progression. Kaplan–Meier analysis was used to estimate the
probability of survival as a function of time, and differences in
the survival of subgroups of patients were evaluated with the log-rank
test. A P-value of o0.05 was considered statistically significant.
RESULTS
Forced expression of TS reduces the sensitivity of NSCLC
cells to pemetrexed
To investigate whether the level of TS expression affects the
sensitivity of NSCLC cells to pemetrexed, we first established A549
(A549/TS1 and A549/TS2), H1299 (H1299/TS1 and H1299/TS2),
and PC9 (PC9/TS1 and PC9/TS2) cells that stably overexpress TS.
Cells that stably harbour the corresponding empty vector (A549/
Mock, H1299/Mock, and PC9/Mock) were established as controls.
Immunoblot analysis showed that the abundance of TS was
markedly increased in the TS-overexpressing lines compared with
the parental or Mock cells (Figure 1A). The enzymatic activity of
TS was also substantially higher in the TS-overexpressing cells
than in the parental or Mock cells (Figure 1B). We then examined
the effect of forced expression of TS on the cytotoxicity of
anticancer drugs as determined with the MTT assay. The median
inhibitory concentration of pemetrexed for the TS-overexpressing
cells was about three to six times that for the corresponding Mock
cells for all three lung cancer lines, whereas cisplatin and docetaxel
inhibited the growth of the TS-overexpressing cells in a manner
similar to that observed with the corresponding Mock cells
(Table 1). To exclude the possibility that these results were
because of nonspecific effects of transfection, we depleted A549/
TS1, H1299/TS1, and PC9/TS1 cells of TS by RNA interference.
Immunoblot analysis revealed that transfection of these cells with
an siRNA specific for TS mRNA resulted in downregulation of the
corresponding protein (Figure 2A). This reduction in
the abundance of TS restored the sensitivity of the cells to the
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Figure 3 Effects of pemetrexed and cisplatin on DNA synthesis in NSCLC cells overexpressing TS. The indicated NSCLC cell lines were cultured for 48h
in complete medium containing various concentrations of pemetrexed (A) or cisplatin (B), after which BrdU incorporation was assessed as described in
Materials and methods section. Data are means±s.d. of triplicates from experiments that were repeated a total of three times with similar results. *Po0.05
vs the corresponding value for Mock cells (Student’s two-tailed t-test). NS, not significant.
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sinhibitory effect of pemetrexed on cell growth (Figure 2B). These
data thus indicated that high TS expression levels reduce the
sensitivity of NSCLC cells to pemetrexed.
Effects of chemotherapeutic agents on DNA synthesis and
apoptosis in TS-overexpressing NSCLC cell lines
We next investigated the effects of TS overexpression on DNA
synthesis and apoptosis in NSCLC cells exposed to pemetrexed,
given that the cytotoxic activity of pemetrexed is due to inhibition
of DNA synthesis and subsequent induction of apoptosis. Assay of
BrdU incorporation revealed that pemetrexed inhibited DNA
synthesis in Mock cell lines in a concentration-dependent manner,
whereas this effect was much less pronounced in the
TS-overexpressing lines (Figure 3A). In contrast, the concentra-
tion-dependent inhibition of DNA synthesis by cisplatin was
largely unaffected by forced expression of TS (Figure 3B). An
annexin V binding assay also revealed that the frequency of
apoptosis was markedly increased by pemetrexed in a concentra-
tion-dependent manner in Mock cells, whereas pemetrexed had
little effect on apoptosis in cells overexpressing TS (Figure 4A). To
confirm that this attenuation of pemetrexed-induced apoptosis in
TS-overexpressing cells was due to the forced expression of TS, we
depleted the TS-overexpressing cells of TS by transfection with the
TS siRNA and then examined the effect of pemetrexed on
apoptosis. Downregulation of TS expression restored the sensiti-
vity of these cells to the proapoptotic effect of pemetrexed. In
contrast to pemetrexed, cisplatin increased the proportion of
apoptotic cells among Mock and TS-overexpressing cells to similar
extents (Figure 4C). These data thus suggested that the effects of
pemetrexed on DNA synthesis and apoptosis are inversely related
to the level of TS expression.
Effects of pemetrexed on the growth of TS-overexpressing
NSCLC cells in vivo
We next investigated whether TS-overexpressing NSCLC cell lines
might exhibit resistance to pemetrexed treatment in xenograft
models. When their tumours became palpable, athymic nude mice
were divided into two groups and treated with vehicle or
pemetrexed for 3–4 weeks. Although pemetrexed significantly
inhibited the growth of tumours formed by Mock cells of the A549,
H1299, or PC9 lines, it did not exhibit such an effect with tumours
formed by the corresponding TS-overexpressing cells (Figure 5).
These data thus suggested that the antitumour effect of pemetrexed
is suppressed by TS overexpression in NSCLC cells, consistent with
our results obtained in vitro.
TS expression in tumours of NSCLC patients treated with
pemetrexed
To evaluate the relation between the level of TS expression in
NSCLC tumours and the clinical response to pemetrexed, we
performed semiquantitative immunohistochemical analysis on
tumour biopsy specimens from 24 patients with advanced NSCLC
treated with pemetrexed combined with platinum agents
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Figure 4 Effects of pemetrexed and cisplatin on apoptosis in NSCLC cells overexpressing TS. (A and C) The indicated NSCLC cell lines were cultured
for 72h in complete medium containing various concentrations of pemetrexed (A) or cisplatin (C), after which the proportion of apoptotic cells was
assessed by staining with fluorescein isothiocyanate-conjugated annexin V and propidium iodide followed by flow cytometry. (B) The indicated NSCLC cell
lines were cultured for 72h in complete medium containing the indicated concentrations of pemetrexed with or without nonspecific (control) or TS siRNAs,
after which the proportion of apoptotic cells was assessed as in A and C. All data are means±s.d. of triplicates from experiments that were repeated a total
of three times with similar results. *Po0.05 (Student’s two-tailed t-test). NS, not significant.
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s(Figure 6A). The characteristics of the patients are shown in
Table 2. Tumours were categorised as either responding (CR or
PR) or non-responding (SD or PD). The level of TS expression for
non-responding groups was significantly (P¼0.038) higher than
that for responding groups (Figure 6B). We next carried out ROC
curve analysis to establish the optimal cutoff value for the
HSCORE of TS expression level, yielding a value of 257.5. Patients
with a low level of TS expression (HSCOREo257.5) had a
significantly longer progression-free survival (P¼0.014) than did
those with a high level (HSCOREX257.5) (Figure 6C). These data
thus suggested that TS expression level in advanced NSCLC
tumours is inversely correlated with the response to pemetrexed.
DISCUSSION
In this study, we have investigated the effects of TS overexpression
on the sensitivity of NSCLC cells to pemetrexed. Pemetrexed-
resistant lung cancer cell lines established by stepwise exposure to
increasing concentrations of pemetrexed were recently shown to
contain increased amounts of TS mRNA compared with parental
cells (Ozasa et al, 2010). Other previous studies have also found
that sensitivity to pemetrexed is inversely related to the level of TS
expression in cancer cell lines (Sigmond et al, 2003; Giovannetti
et al, 2008). These observations have suggested that TS gene
expression is associated with resistance to pemetrexed, but the
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Figure 5 Effect of pemetrexed on the growth of TS-overexpressing NSCLC cells in vivo. Nude mice with tumour xenografts established by subcutaneous
implantation of tumour fragments derived from the indicated NSCLC cell lines were treated with vehicle (control) or pemetrexed (100mgkg
 1,
intraperitoneal) on days 1, 8, 15, and 22. Tumour volume was determined at the indicated times after the onset of treatment. Data are means±s.e.m. of
values from eight mice per group. *Po0.05 for pemetrexed vs the corresponding value for vehicle (Student’s two-tailed t-test).
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Figure 6 Relation of TS expression level to tumour response in NSCLC patients treated with pemetrexed and either carboplatin or cisplatin. (A)
Representative sections of carcinomas including cells with the indicated intensities of TS immunostaining. Scale bars, 125mm. (B) TS expression level
(HSCORE) for the clinical specimens of 24 patients classified according to tumour response (response¼CR or PR, n¼7; non-response¼SD or PD,
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smechanism by which a high level of TS expression might result in a
reduced sensitivity to pemetrexed has remained unclear. Thymi-
dylate synthase has a central role in the biosynthesis of
thymidylate, an essential precursor for DNA synthesis (Carreras
and Santi, 1995). We have previously shown that TS expression
level differs among lung cancer cell lines, and that RNA
interference-mediated depletion of TS in such cell lines resulted
in growth suppression through inhibition of DNA synthesis and
induction of apoptosis in a manner independent of the original
level of TS activity (Takezawa et al, 2010). Pemetrexed exerts its
cytotoxic effects through inhibition of multiple DNA synthesis-
related enzymes including TS. We have now shown that
pemetrexed inhibited DNA synthesis and induced apoptosis in
NSCLC cell lines; however, it failed to induce such effects in the
corresponding cells engineered to overexpress TS. Forced expres-
sion of TS also abolished the antitumour effect of pemetrexed in
xenograft models. Our data suggest that pemetrexed did not fully
inhibit TS activity in TS-overexpressing cells, given that DNA
synthesis remained active after pemetrexed exposure. They further
suggest that the observed reduction in the sensitivity of
TS-overexpressing cells to pemetrexed may result from sustained
activity of TS in the presence of the drug. We also examined the
possible effect of pemetrexed on the expression levels of apoptosis-
related molecules in both Mock and TS-overexpressing cells, but
we found that pemetrexed did not substantially alter the
abundance of such proteins including that of XIAP (data not
shown), which we previously identified as having a key role in TS
depletion-induced apoptosis in NSCLC cells (Takezawa et al,
2010). The precise mechanism by which pemetrexed induces
apoptosis thus remains to be determined.
Previous studies have examined the possible relation between TS
expression level and the response to pemetrexed in cancer patients
(Gomez et al, 2006; Righi et al, 2010; Uramoto et al, 2010). In a
phase II trial of pemetrexed monotherapy for advanced breast
cancer (Gomez et al, 2006), 61 patients were treated with
pemetrexed and evaluable for response. This study revealed a
potential association between a high level of TS mRNA and a poor
response to pemetrexed treatment. Another study evaluated TS
expression level immunohistochemically by means of the HSCORE
system in 60 patients with malignant mesothelioma treated either
with the combination of pemetrexed and platinum, or with
pemetrexed alone (Righi et al, 2010). A significant inverse
correlation was found between TS expression level and time to
progression, or overall survival. Finally, no significant correlation
between the abundance of TS mRNA and clinical outcome was
apparent for five NSCLC patients treated with the combination of
pemetrexed and platinum, or with pemetrexed alone (Uramoto
et al, 2010), although the small sample number precluded any
definitive conclusion. In this study, we found that a high level of
TS expression in human NSCLC tumours was significantly
associated with a reduced tumour response and a shorter
progression-free survival in 24 patients treated with pemetrexed
combined with platinum agents, consistent with the previous
studies of patients with breast cancer or malignant mesothelioma
(Gomez et al, 2006; Righi et al, 2010). Given that the anticancer
effects of cisplatin were independent of TS expression level in
NSCLC cell lines, the relation between TS expression level and
clinical outcome observed in our clinical analysis likely reflects the
effect of pemetrexed. We recently evaluated the abundance of TS in
NSCLC tumours of patients treated with carboplatin and paclitaxel,
and neither a prognostic nor predictive role was identified for TS
expression level in these patients (Takeda et al, 2010). Together
with such observations, our present results suggest that assessment
of baseline TS expression may be of predictive value in evaluation
of chemosensitivity to pemetrexed in NSCLC. Although we cannot
exclude a contribution of factors other than TS expression level to
pemetrexed chemosensitivity, our preclinical and clinical data
provide a rationale for the potential use of TS expression level as a
predictive biomarker for response to pemetrexed or pemetrexed-
based chemotherapy in patients with NSCLC. Further investigation
is needed with a larger cohort of patients or in prospective studies
to confirm this conclusion.
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